3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
12
NIH
5
NETWORK
2
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
209
Stomach Neoplasms
37
Neoplasm Metastasis
26
Neoplasms
18
HER2-positive Breast Cancer
14
Colorectal Neoplasms
14
Carcinoma, Non-Small-Cell Lung
10
Brain Neoplasms
10
Esophageal Neoplasms
5
Triple Negative Breast Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
4
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Endometrial Neoplasms
4
Adenocarcinoma Of Esophagus
4
Uterine Cervical Neoplasms
3
Urologic Neoplasms
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
HER2-positive Gastric Cancer
3
Carcinoma
3
Breast Cancer Metastatic
3
Urinary Bladder Neoplasms
2
Solid Tumors
2
Sarcoma
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Melanoma
2
HER2-positive Early Breast Cancer
2
Cholangiocarcinoma
2
Breast Diseases
2
Interventions
pembrolizumab
2
Lapatinib
2
pertuzumab
1
pazopanib
1
bemcentinib
1
Trastuzumab
1
Surgical Procedures, Operative
1
Radiotherapy
1
Injections, Subcutaneous
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Inflammatory Breast Neoplasms
×
Trastuzumab
×
Clear all
NCT05415215
2026-02-10
ProHer
Hoffmann-La Roche
Phase 3
Completed
346 enrolled
20 charts